Get More Info from Inflammatix
Chat With Us
About Our Organization
Inflammatix, Inc., a pioneering molecular diagnostics company headquartered in Sunnyvale, California, USA, is developing novel diagnostics that rapidly read a patient’s immune system to improve patient care and reduce major public health burdens. It’s lead product, the TriVerity™ Acute Infection and Sepsis Test is designed to inform on the likelihood of a bacterial infection, a viral infection, and illness severity in adult patients with suspected acute infection or sepsis that present to US emergency departments. The TriVerity Test thus aims to aid physicians to confidently make treatment decisions, including selection of antimicrobial therapy, administering additional diagnostic testing, and whether to admit or discharge the patient. TriVerity and future tests are designed to be performed on the company’s proprietary Myrna™ Instrument, a cartridge-based benchtop analyzer that is capable of multiplex sample-to-answer quantitation of mRNAs in about 30 minutes. For more information, please visit www.inflammatix.com and follow the company on LinkedIn and X (formerly Twitter) at @Inflammatix_Inc.
Inflammatix product development has been funded in part with Federal funds from the
Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. 75A50119C00034 and 75A50119C00044.
TriVerity, Myrna, and Inflammatix are trademarks of Inflammatix, Inc. in the US and other
countries and regions. >span class="NormalTextRun SpellingErrorV2Themed SCXW101368892 BCX0">TriVerity Acute Infection and Sepsis Test System is not for sale and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Downloadable Handouts
-
Inflammatix TriVerity FactSheetYou must log in to access content.
Booth Staff
There are no matching speakers.
Access Date | Quiz Result | Score | Actions |
---|